Large-Scale, Deep, and Unbiased Plasma Proteomics for a Multi-Cancer Biomarker Discovery Study

Bruce Wilcox, VP of Proteomics at PrognomiQ, Inc., presents data from a biomarker discovery feasibility study of 212 subjects (cancer vs non-cancer) that demonstrates how the Proteograph™ Product Suite, combined with the timsTOF Pro2, creates deep proteome coverage at high throughput with reproducibility for large-scale proteomics studies.
PrognomiQ’s uses a multi-omics platform for interrogating complex diseases, with proteomics playing an important role. Watch how the Proteograph Product Suite has provided enhanced proteome coverage to detect known cancer-related proteins at eight orders of magnitude, helping drive innovation in cancer detection and care.
A presentation from HUPO Reconnect 2021.
=== Key Topics ===
0:00 - Introduction
2:05 - Early cancer detection innovations
3:10 - PrognomiQ’s approach
5:25 - Evaluation of the Proteograph Product Suite and timsTOF Pro2
9:10 - The detection of more than 5,000 proteins
11:25 - Configuring a robust Proteograph workflow with LC-MS
18:45 - Data from a multi-cancer study
19:55 - Conclusion and acknowledgements
=== Resources ===
✭ Visit Seer’s Scientific Presentations Playlist:
• Scientific Presentations
=== Stay Connected With Seer ===
✭ To learn how Seer is empowering the scientific community through the power of proteomics, visit: seer.bio
✭ Subscribe to Seer’s KZbin channel for more on proteomics analysis and innovations kzbin.info?sub...
✭ Join Seer on LinkedIn
/ seerbio
✭ Join Seer on Twitter
/ seer_bio
#Seer #proteomics #proteomicsanalysis #SeerBiotech #plasmaproteomics #Proteograph #AskSeerScientists #lcms #unbiasedproteomics #nextgenproteomics #PrognomiQ